cyrilzakka/clinical-trials huggingface dataset:
Collagen-povidone for Diabetic Seniors' Tenosynovitis

Diabetes affects 415 million adults globally, leading to hand issues. Povidone collagen shows promise in managing tenosynovitis. A clinical trial was conduced to compared its efficacy in adults over 60. It is shown that the intervention reduces pain, improves functionality, and grip strength with no complications. Collagen povidone holds potential for treating diabetic hand issues.

A randomized clinical trial from January 2022 to January 2023 compared povidone collagen intervention with a placebo in adults aged 60 and above suffering from stenosing tenosynovitis. Participants were randomized into Case (collagen-povidone) and Control (physiological solution) groups. The study evaluated parameters like tenosynovitis, diabetes, pain, functionality, and grip strength.

Eligibility Criteria:
Inclusion Criteria:

* Diagnostic of stenosing tenosynovitis
* Diagnostic of diabetes
* Adults aged 60 or older

Exclusion Criteria:

* Adults aged 60 or older
Central Incisors Narrow Implants in Alternative to Bone Augmentation With 4.2 mm Implants .

Horizontal bone augmentation procedures are commonly used to increase bone width to allow the placement of dental implants or to improve aesthetics in deficient areas. Smaller diameter implants could be used instead in order to avoid bone augmentation procedures.

The comparison between these two solutions will be evaluated in the trial.


Eligibility Criteria:
Inclusion Criteria:

* Upper central incisor edentulism
* bone width between 3.5-4.5 mm
* requirement of only one implant supported crown
* patient is willing to sign an informed consent

Exclusion Criteria:

* General contraindications to implant surgery.
* Immunosuppressed or immunocompromised patients
* Patients irradiated in the head and neck area.
* Patients with poor oral hygiene and motivation.
* Uncontrolled diabetes.
* Pregnancy or lactation.
* Addiction to alcohol or drugs.
* Untreated periodontal disease.
* Treated or under treatment with intravenous amino-biphosphonates.
* Poor oral hygiene and motivation.
* Psychiatric problems and/or unrealistic expectations.
* Acute infection (abscess) or suppuration in the area intended for implant placement.
* Patients referred only for implant placement if cannot be followed at the treatment centre.
* Patient unable to attend the follow-up controls for 3 years after implant loading.
* Patient included in other studies, if this protocol cannot be properly followed.
* Immediate post-extractive sites (to be eligible at least 3 months must have passed since extraction).
Acute Effect of Static Stretching and Pilates Stretching on the Muscle Strength

Introduction: Studies have shown that static stretching performed immediately before strength exercises impairs performance. However, unlike static stretching, dynamic stretching performed immediately before muscular strength exercises does not seem to result in worse performance, and in some cases may even provide greater strength performance. Still, the literature is controversial and inconclusive to date.

Objective: To verify the acute effect of static stretching versus dynamic stretching on the muscle strength of young university students.

Methods: The sample will consist of 102 physically active young university students, of both sexes, aged between 18 and 25 years old, subdivided into three groups: Group 1 - static stretching; Group 2 - dynamic stretching; and Group 3 - control. Everyone will undergo assessment of the isokinetic peak torque of the knee extensor and flexor muscles at 60º/s and 180º/s in the dominant lower limb. Next, the experimental groups (Groups 1 and 2) will perform static or dynamic stretching exercises for the quadriceps and hamstring muscles, while the control group will not perform any activity. Finally, everyone will undergo muscle strength assessment again according to the same procedures used initially. Analysis of covariance (ANCOVA) will be used to compare groups, with data from the initial assessment as adjustment covariates.


Eligibility Criteria:
Inclusion Criteria:

* to practice systematic physical exercises at least three times a week over the last six months;
* healthy young adults, aged between 18 and 25 years;
* agree to participate in the study by signing the Free and Informed Consent Form.

Exclusion Criteria:

* musculoskeletal injuries in the lower limbs;
* pregnancy.
Comparison Between Two Optional IVC Filters Regardind Ease of Use,Complications and Outcome

OptEase filters are easier to retrieve but the dwell time is shorter than the Gunter filters. There are more thrombi on the OptEase than on the Gunter at the time of retrieval. OptEase filter has a better infitration capabillity due to its diamond shape. OptEase filters will hjave more IVC occlusions as a complication.

We will isert the two filters blindly. We will follow the patients clinically and if needed we will add imaging exams. We will try to retrieve most filters.

Eligibility Criteria:
Inclusion Criteria:

* All patients referred for filter insertion

Exclusion Criteria:

* Young age (\<18 years)
Efficacy Evaluation of Wasabi Leaf Extract on Skin

To assess the efficacy of Wasabi Leaf Extract on skin


Eligibility Criteria:
Inclusion Criteria:

* 20 to 65-year-old males or females
* People with dull skin, pigmentation spots or acne-prone, acne scars
* Acne severity assessment- Investigator's Global Assessment Scale (IGA) ≥ 2

Exclusion Criteria:

* Received medical cosmetic treatment (including cosmetic skin care, laser, fruit acid peeling, injection or plastic surgery, etc.) currently or within one month before the trial
* Outdoor workers (exposed to the sun more than 5 hours a day)
* People who are breastfeeding, pregnant or planning to become pregnant during the test (self-report)
* People with heart, liver, kidney, endocrine and other major organic diseases (self-reported)
* People who have undergone major surgery (according to medical history)
* People who take drugs for a long time
* People with mental illness
* Students who are currently taking courses taught by the principal investigator of this trial
Comparison of Preoperative Inhaled Budesonide With Salbutamol on the Respiratory Adverse Effects in Children Undergoing Tonsillectomy

Comparison of preoperative inhaled Budesonide with Salbutamol on the incidence of respiratory adverse effects in children undergoing tonsillectomy

Comparison of preoperative inhaled Budesonide with Salbutamol on the incidence of respiratory adverse effects in children undergoing tonsillectomy Adenotosillectomy is routinely performed for children with sleep disordered breathing or recurrent infectious tonsillitis. Although the safety of the pediatric anesthesia is constantly improving, a substantial proportion of children undergoing tonsillectomies experience pre operative respiratory adverse events with a prevalence up to 50% in children with at least one risk factor. Both minor adverse effects such as oxygen desaturation airway, obstruction coughing or wheezing and the major events such as laryngospasm and/ or bronchospasm occur more commonly undergoing tonsillectomy compared with other non airway surgery.

Eligibility Criteria:
Inclusion Criteria:

1. children scheduled for elective tonsillectomy with or without adenoidectomy, grommets cautery of inferior turbinates.
2. Age more than or equal 5 years and less than or equal to 12 years.
3. Both genders
4. No obvious abnormalities in preoperative ECG, blood routine electrolytes and other tests.
5. ASA class 1

Exclusion Criteria:

1. Patients with Known hypersensitivity to any of the drugs that would be used in the study
2. Patients that are immunologically compromised
3. Sleep apnea syndrome or difficult airway
4. Pre-existing hypoxemia is SpO2 \< 90%
5. History of adverse events with prior sedation or patients who had taken any sedative drugs within the last 24 hours.
6. Parents refusal
Pregnant Women s Views About the Ethics of Prenatal Whole Genome Sequencing

Background:

Prenatal whole genome sequencing (PWGS) will give expecting parents large amounts of genetic data about their baby. This raises ethical concerns. Researchers want to find out if women want access to the kind of data PWGS provides. They want to know why and under what circumstances women would or would not want the data.

Objective:

To explore the views of pregnant women about possible use of PWGS. To find out whether they would want different categories of genetic data, and how they would use such findings.

Eligibility:

Women ages 18 and older who pregnant and speak English or Spanish

Design:

Participants will be recruited by their doctors.

Participants will take a survey about their views of PWGQ. They may take it online or on paper.

The impending implementation of prenatal whole genome sequencing (PWGS) raises a host of ethical concerns given the massive amounts of genetic information that expecting parents will be able to learn about their baby. This project involves a cross-sectional quantitative survey of pregnant women to explore whether they want access to the kinds of information provided by PWGS, why and under what circumstances. The survey will address questions such as: What sorts of information do pregnant women want to know about their baby, and why? What, if anything, would they do with the information? What kind of guidance would pregnant women like from their medical team regarding fetal genetic testing? Given the range of practical and ethical challenges posed by PWGS, our data will inform practitioners approaches towards PWGS as the technology develops and becomes more widely available. It is imperative that government regulators and professional societies take into account the views of people directly affected by any policies that are created - including patients themselves - before crafting rules for whether, when and how to utilize PWGS.

Eligibility Criteria:
* INCLUSION CRITERIA:
* Participants must be 18 years of age
* Participants must be pregnant
* Participants must speak English or Spanish
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.

This study compares in the first study period combination of Irinotecan with three different methods of administration by Fluoropyrimidine. (ie. infusion, bolus and oral). In the second period of study it compares FOLFIRI \[a chemotherapy regime that combines bolus irinotecan and leucovorin \[LV\] with infusional 5-fluorouracil (5-FU)\] + bevacizumab and mlFL + bevacizumab. Measures of efficacy and safety will be reported.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of colorectal cancer (either newly diagnosed or recurrent disease) with evidence of metastatic disease. (Stage IV distant disease)
* Present or past histological documentation of adenocarcinoma of the colon or rectum. The site of the primary lesion must be or have been confirmed endoscopically, radiologically, or surgically to be or have been in the large bowel. Patients with a history of colorectal cancer treated by surgical resection who develop radiological or clinical evidence of metastatic cancer do not require separate histological or cytological confirmation of metastatic disease unless:
* An interval of greater than five years has elapsed between the primary surgery and the development of metastatic disease.
* The primary cancer was a Duke's A or B1.
* Physicians should consider biopsy of lesions to establish the diagnosis of metastatic colorectal cancer in each case if there is substantial clinical ambiguity regarding the nature of source of apparent metastases.

Exclusion Criteria:

* Patients who received any prior systemic anticancer therapy for metastatic colorectal cancer (e.g., chemotherapy, antibody therapy, immunotherapy, gene therapy, vaccine therapy, cytokine therapy, or other experimental agents).
* Patients cannot have concurrent malignancies at study entry.
* Exceptions: Patients with prior non-colorectal malignancies will be eligible if they have been disease-free for ³ 3 years or are deemed at low risk for recurrence by their treating physician (e.g., early stage prostate cancer, melanoma or bladder cancer). Patients with squamous or basal cell carcinoma of the skin or in situ cervical cancer that have been effectively treated are eligible, even if these were diagnosed within 3 years before randomization.
Influence of the Global Postural Reeducation and the Personality in the Posture

Determine the influence of a treatment with Global Postural Reeducation techniques and the personality traits in the stabilometric parameters

This study is realized with university students. For a first objective of this study, all the participants complete the "big five questionnaire" to determine their personality traits and then the subjects are analyzed with a stabilometric platform and cervical/lumbar range of motion (ROM) to determine their basal parameters. The personality traits and the basal stabilometric parameters like the postural sway, will be crossed to investigate a possible relation. For a second objective, the randomized study of the effectiveness of the Global Postural Reeducation (GPR) in the stabilometric parameters, the subjects are divided in a experimental group or in a control group. Experimental group is treated in a 45 minutes GPR session, with three postures: the first is for stretch the anterior muscular chain with the patient lying supine on a couch with arms at 45 degrees, hips open, and feet in opposition on top of the couch. This posture is maintained 25-30 minutes. In the second GPR posture, to stretch the posterior muscular chain, the subject is positioned with legs elevated, for 12-15 minutes. Third position is with the participant in upright standing posture 2-5 minutes to integrate the postural corrections. During all the time, the physiotherapist uses manual therapy for stretch the muscles under the official rules of GPR techniques. Group control do not receive any technique. After the time of the intervention or no intervention, a second measure of stabilometric parameters and ROM is taken. After this first day, two days later and seven days later, the measures are repeated to determinate the permanence of the effects of GPR techniques.

The improvement will be assessed by calculating indicators of clinical relevance: relative risk (RR), absolute risk reduction (AR). The results will be compared statistically to determine some possible relation. The confidence intervals (CI) will be calculated for the most relevant parameters. The analysis will be made with a statistics program (SPSS 19.0)

Eligibility Criteria:
Inclusion Criteria:

* College students spend 4 hours or more per day sitting

Exclusion Criteria:

* College students do not spend 4 hours or more per day sitting.
* Subjects with a traumatic problem, injuries, in the moment of the study, or subject in treatment of this injuries
Textured Food Introduction Information and Parental Feeding Practices

The purpose of this study is to conduct an intervention with 60 parents of 8 months old children to test the effect of recommendations, compared to usual care, promoting the introduction of textured foods between 8 and 15 months on parental practices of use of textured foods and the effect of such practices on children acceptance for a variety of textured foods.

The intervention tests the effect of providing parents with recommendations on textured food introduction between 8 and 15 months on their practices of offering of textured foods and their child's acceptance of textured foods. The intervention consists of advice and tips on the why and how introducing textured food during complementary feeding, which were not address in French national guidelines (Programme National Nutrition Santé (PNNS)) at the start of the study. Advise were developped from current literature knowledge and recommendations in other countries. They are accompanied with monthly counselling via phone calls by dietician and two baskets containing food preparation utensils and commercial textured foods. The intervention group (n=30) benefits from this intervention. The control group (n=30) receive general information on healthy eating provided by the food guides of the PNNS, phone calls collecting general information and 2 baskets containing baby gifts.

Acceptance is evaluated experimentally pre and post intervention in a laboratory setting evaluating children swallowing foods of different textures.

Eligibility Criteria:
Inclusion Criteria:

* parents ages ≥ 18 years old
* children born full term (≥37 weeks) and with weight ≥2500 g
* children introduced to complementary feeding after 4 months and before 6 months

Exclusion Criteria:

* children with episode of tube feedings, chronic disease, allergy and gastroesophageal reflux requiring medication
* children introduced to complementary feeding with baby-led weaning method
* children already involved in another study on eating behaviour
Effectiveness and Safety of Intra-articular SEMICAL GEL-B CROSS Therapy in Knee Osteoarthritis (SEM-ART1)

The goal of this clinical trial is to evaluate the effectiveness and safety of intra-articular injection of a cross-linked sodium hyaluronate; SEMICAL GEL-B CROSS, in knee osteoarthritis.

Primary objectives: The aim of this study is to obtain short- and long-term clinical data on the performance and safety of intra-articular injection of SEMICAL GEL B-CROSS, produced and marketed by Semical Biosurgery incorporated company, in knee osteoarthritis patients.

It is also aimed to monitoring known adverse events and complications, detecting previously unknown adverse events and complications, to identify and analyze emerging risks based on real-life data. Participants will receive intra-articular injection of either a cross-linked sodium hyaluronate (SEMICAL GEL-B CROSS); or placebo (isotonic saline solution) at baseline, and will be followed-up for one year to compare the effectiveness and safety of the given therapy.

The study is a randomized controlled, double-blind, two-armed, single-center and cross-over study. After a maximum screening period of 28 days, patients with Kellgren \& Lawrence Stage II and III knee osteoarthritis will be randomly assigned to one of the two treatment arms on the day of injection, which is considered Day 0. These treatment arms are:

Group 1: Treatment Arm - Cross-linked intra-articular hyaluronic acid (90 mg 3 ml cross-linked hyaluronic acid)

Group 2: Control Arm - Intra-articular isotonic saline solution (3 ml 0.9% isotonic saline) A safety visit will be made 7-10 days after administration of the treatment injection and the injection site will be visually evaluated for local reactions. In addition, an inquiry for injection-related adverse events will also be conducted.

Treatment responses of patients in both groups will be evaluated by a separate researcher blinded to study treatment with predefined objective response criteria.

At the 3rd month visit, the patients in both groups will be crossed-over and those who received a placebo at baseline will receive a hyaluronic acid injection at the 3rd month, while those who receive a hyaluronic acid injection at baseline will receive a placebo at the 3rd month. Efficacy evaluations will continue to be made at every three months for one year.

Eligibility Criteria:
Inclusion Criteria:

* Adults aged 18 and over, both male and female
* Diagnosed with clinical knee osteoarthritis according to the American College of
* Rheumatology (ACR) criteria, with Kellgren \& Lawrence stage II and III osteoarthritic findings on antero-posterior knee radiographs
* Able to provide written informed consent

Exclusion Criteria:

-
Longitudinal Effectiveness of HEART Smartphone- Based Videoconferencing Program in Enhancing Residents and Family'Health

This study intends to understand the longitudinal effectiveness of the smartphone- based Helper of Emotional Assessment ＆Relationship Teaching (HEART) videoconferencing program in enhancing residents and family health through the employment of a sequential-methods, triangulation research design.

In the phase I lasing 18 months, it will employ: (a) a web-based RT/communication education programs which is develop based on understanding the experience of videoconferencing visit from family in nursing home, and (b) a HEA system which is for real-time face emotion recognition system used in videoconferencing will be developed and tested. In the phase II occupying the second 18 months it will evaluate the longitudinal effects of the HEART program on residents' and family's health change over time (baseline, 1 month, 3 months, and 6 months).

Nursing homes in Taiwan will be automated computerized blocked randomly assigned to three groups: (a) An RT group, which receives the RT program and uses 3 months' smartphone-based videoconferencing without the HEA system, (b) A HEART group, which receives the RT program and uses 3 months smartphone-based videoconferencing along with the HEA system, and(c) A control group, which has only smartphone-based videoconferencing visits.


Eligibility Criteria:
Inclusion Criteria:

1. residents were aged equal or higher than 60 years, resident's family were aged equal or higher than 20 years.
2. both residents and family could communicate in Mandarin or Taiwanese
3. both residents and family have no serious hearing problems
4. residents has a MMSE score equal or higher than 16 for residents with no formal education or higher than 24 for residents with at least a primary school education
5. both residents and family agree to participate,
6. family is the significant member of residents, such as caregivers.

Exclusion Criteria:

-
Direct Peritoneal Resuscitation for Intra-abdominal Catastrophes

It is a retrospective study. Patients, who presented with either traumatic or general surgery emergencies, undergone exploratory laparotomy, had an open abdomen management and received Direct Peritoneal Resuscitation in addition to standard resuscitation will be considered as meeting the criteria to collect the data.

Due to the high volume of patient transfers from different facilities with difficult intra-abdominal pathologies and the high case-mix index at Westchester Medical Center, we see many patients who require re-operations and open abdominal management. Since July1st of 2020 we have been using DPR in addition to standard iv fluids on all patients who undergo open abdominal management and it is now standard of care at our facility. we plan to collect the data from all qualified subjects who received DRP since 7/1/2020 to 6/30/2022.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients 18 years of age or older.
* Trauma or General surgery patients who undergo emergency abdominal surgery via laparotomy and who had open abdominal management during the index procedure at our institution.
* Patients who are transferred to our institution with an already open abdomen will also be eligible if they required continued open abdominal management.

Exclusion Criteria:

* Patients \<18 years are excluded.